Biosimilars for Entyvio: Are Any FDA-Approved?

There are no FDA-approved biosimilars for Entyvio in the United States as of August 10, 2026. Entyvio is available in intravenous and subcutaneous forms, which can make a formulation change look like a product substitution. The FDA list contains no vedolizumab product referencing Entyvio. A switch between Entyvio infusion and Entyvio injection therefore remains a change within the reference brand, not a biosimilar switch.

Are there biosimilars for Entyvio?

The FDA Purple Book record for Entyvio identifies vedolizumab as the proper name, Takeda Pharmaceuticals U.S.A. as the applicant, and Entyvio as a 351(a) product. A future vedolizumab biosimilar would have its own 351(k) license and a distinct nonproprietary suffix. No such U.S. product currently appears in FDA's approved biosimilar directory.

Entyvio also has no conventional generic. The FDA patient guide explains that biologics are complex medicines made from living sources and that approved follow-on versions use the biosimilar pathway. A foreign approval, development program, or clinical-trial candidate is not an FDA-approved Entyvio biosimilar. The U.S. approval must appear in FDA's product list and Purple Book before patients or plans can treat it as one.

Entyvio infusion and injection are the same brand

The current Entyvio prescribing information includes adult Crohn's disease and ulcerative colitis and describes intravenous and subcutaneous presentations. The Purple Book lists the subcutaneous prefilled syringe and Entyvio Pen under the vedolizumab reference product. Those products share the Entyvio brand and active ingredient.

A move from an infusion center to self-injection changes the route, dosing logistics, dispensing channel, and patient experience described in the Entyvio label. It does not introduce a biosimilar. A review of 36 real-world reports evaluated transitions from intravenous to subcutaneous vedolizumab and reported maintained effectiveness and safety outcomes across the collected studies. That evidence concerns formulation switching with vedolizumab and provides no FDA biosimilarity determination for another manufacturer.

Why other IBD biologics are not Entyvio biosimilars

A therapy can treat the same disease and still be a different biological product. The FDA review framework requires a proposed biosimilar to be compared with a named reference product and shown to be highly similar with no clinically meaningful differences. Different active ingredients, targets, doses, or reference applications represent separate therapies even when they share an IBD indication.

This distinction matters when reading an insurer letter. Language about an "alternative," "preferred biologic," or "step therapy" may describe a change to another drug. Language about a biosimilar should include the exact product name and suffix that can be checked against FDA records. Ask the gastroenterology office to review any proposed change in active ingredient because it involves a treatment decision beyond substitution within the vedolizumab family.

Insurance implications for Entyvio

The infusion and injection routes can be handled through different benefits. Clinician-administered Entyvio commonly involves the medical benefit and infusion-site authorization, while a self-injected product may involve the pharmacy benefit and specialty pharmacy. CMS publishes payment information for Part B biological products, and commercial plan rules vary. Confirm the controlling benefit, approved route, provider or pharmacy, authorization dates, and patient cost before changing formulations.

The Crohn's & Colitis Foundation's biosimilar guidance recommends asking which product is covered, when a change takes effect, where it will be supplied, what it will cost, and whether an appeal is available. Even without an Entyvio biosimilar, those questions remain useful when a plan changes route, site of care, or preferred therapy. Save the authorization and the exact vedolizumab order with the next dose date.

How to verify future Entyvio biosimilar news

Start with the live FDA biosimilar list, then confirm the license relationship in the Purple Book. An FDA-approved Entyvio biosimilar should have a proprietary name, a vedolizumab suffix, an applicant, an approval date, and a 351(k) designation referencing Entyvio. Marketing availability may begin later than approval, so the specialty pharmacy or infusion center must also confirm inventory.

For now, the answer to "biosimilars for Entyvio" is zero in the United States. Patients may still encounter a branded route change or a plan request for another IBD drug. Checking the exact name and active ingredient separates those situations and gives the care team the information needed to protect treatment continuity.

Keep the current infusion date or injection schedule beside every authorization notice. If a plan changes the route or supplier, ask which office must issue the new order and whether the current approval remains active during review. Record the insurer's case number, the provider's submission date, and the supplier's inventory response. This timeline makes an access problem easier to escalate before the next vedolizumab dose is due.